Advisors Asset Management Inc. Boosts Stock Holdings in United Therapeutics Corporation $UTHR

Advisors Asset Management Inc. grew its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 40.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,892 shares of the biotechnology company's stock after acquiring an additional 1,129 shares during the quarter. Advisors Asset Management Inc.'s holdings in United Therapeutics were worth $1,200,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the company. Hohimer Wealth Management LLC boosted its holdings in United Therapeutics by 0.3% during the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock worth $3,900,000 after acquiring an additional 37 shares during the last quarter. Applied Finance Capital Management LLC raised its stake in shares of United Therapeutics by 3.7% during the 1st quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company's stock worth $349,000 after purchasing an additional 40 shares during the period. Headlands Technologies LLC raised its stake in shares of United Therapeutics by 1.5% during the 1st quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company's stock worth $828,000 after purchasing an additional 40 shares during the period. First Financial Bankshares Inc raised its stake in shares of United Therapeutics by 0.3% during the 1st quarter. First Financial Bankshares Inc now owns 13,769 shares of the biotechnology company's stock worth $4,245,000 after purchasing an additional 42 shares during the period. Finally, Cadence Bank raised its stake in shares of United Therapeutics by 1.2% during the 1st quarter. Cadence Bank now owns 3,963 shares of the biotechnology company's stock worth $1,222,000 after purchasing an additional 47 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Nilda Mesa sold 645 shares of the company's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the sale, the director directly owned 4,883 shares in the company, valued at $1,416,021.17. This represents a 11.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Richard Giltner sold 3,036 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the sale, the director owned 19,384 shares in the company, valued at approximately $5,613,606.40. This represents a 13.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 106,181 shares of company stock valued at $35,537,239. 10.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on UTHR shares. Jefferies Financial Group lifted their target price on United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. lowered their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 8th. Morgan Stanley lowered their target price on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. Bank of America lifted their target price on United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 2nd. Finally, HC Wainwright lifted their target price on United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research note on Friday. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $429.62.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $394.62 on Tuesday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $436.95. The stock's 50-day simple moving average is $309.83 and its 200 day simple moving average is $305.60. The stock has a market capitalization of $17.80 billion, a P/E ratio of 15.40, a P/E/G ratio of 6.11 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. During the same quarter in the prior year, the firm posted $5.85 earnings per share. The company's revenue was up 11.7% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.